bms 986202 Search Results


bms 986202  (MedChemExpress)
93
MedChemExpress bms 986202
TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
Bms 986202, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bms 986202/product/MedChemExpress
Average 93 stars, based on 1 article reviews
bms 986202 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
compounds bms- 986202  (Bristol Myers)
90
Bristol Myers compounds bms- 986202
TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or <t>TYK2i</t> <t>BMS-986202</t> (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.
Compounds Bms 986202, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compounds bms- 986202/product/Bristol Myers
Average 90 stars, based on 1 article reviews
compounds bms- 986202 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or TYK2i BMS-986202 (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.

Journal: eBioMedicine

Article Title: Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice

doi: 10.1016/j.ebiom.2025.105734

Figure Lengend Snippet: TYK2 inhibition reduces the onset of diabetes in the RIP-LCMV-GP mouse model of T1D . ( a ) Male RIP-LCMV-GP mice were inoculated at 8 weeks of age with LCMV stock (0.5 × 10 5 PFU I.P., Armstrong strain), and blood glucose levels were measured pre-inoculation (Pre) and on days 1, 4, 7, 11, and 14 post-inoculation. Mice were pre-treated with either vehicle or TYK2i BMS-986202 (30 mg/kg/day) for 2 days prior to inoculation, and treatment continued until the study end on day 14. n = 18 mice/group. Vehicle- and TYK2i-treated groups are shown in grey and red symbols or bars, respectively. ( b ) Kaplan–Meier diabetes incidence plot for vehicle- and TYK2i-treated groups. ( c ) Blood glucose levels of vehicle- and TYK2i-treated mice. All blood glucose data are presented as mean with 95% CI, with individual data points represented: significant differences determined by Log-rank (Mantel–Cox) test.

Article Snippet: Cells were treated with the TYK2i BMS-986165 (MedChemExpress, catalogue #HY-117287) or BMS-986202 (a kind gift from Bristol Myers Squibb) at different concentrations ranging from 0.0003 to 3 μM and with different proinflammatory cytokines alone or in combination: IFNα (2000 U/mL, PeproTech, catalogue #300-02AA-1MG), IL-1β (50 U/mL, R&D Systems, catalogue #201-LB-005), and TNFα (1000 U/mL, PeproTech, catalogue #300-01A-50UG).

Techniques: Inhibition